{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,20]],"date-time":"2026-05-20T17:06:53Z","timestamp":1779296813974,"version":"3.51.4"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,6,1]],"date-time":"2020-06-01T00:00:00Z","timestamp":1590969600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,6,1]],"date-time":"2020-06-01T00:00:00Z","timestamp":1590969600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Rare or orphan diseases affect only small populations, thereby limiting the economic incentive for the drug development process, often resulting in a lack of progress towards treatment. Drug repositioning is a promising approach in these cases, due to its low cost. In this approach, one attempts to identify new purposes for existing drugs that have already been developed and approved for use. By applying the process of drug repositioning to identify novel treatments for rare diseases, we can overcome the lack of economic incentives and make concrete progress towards new therapies. Adrenocortical Carcinoma (ACC) is a rare disease with no practical and definitive therapeutic approach. We apply Heter-LP, a new method of drug repositioning, to suggest novel therapeutic avenues for ACC. Our analysis identifies innovative putative drug-disease, drug-target, and disease-target relationships for ACC, which include Cosyntropin (drug) and DHCR7, IGF1R, MC1R, MAP3K3, TOP2A (protein targets). When results are analyzed using all available information, a number of novel predicted associations related to ACC appear to be valid according to current knowledge. We expect the predicted relations will be useful for drug repositioning in ACC since the resulting ranked lists of drugs and protein targets can be used to expedite the necessary clinical processes.<\/jats:p>","DOI":"10.1038\/s41598-020-65658-x","type":"journal-article","created":{"date-parts":[[2020,6,1]],"date-time":"2020-06-01T10:03:14Z","timestamp":1591005794000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":19,"title":["A computational drug repositioning method applied to rare diseases: Adrenocortical carcinoma"],"prefix":"10.1038","volume":"10","author":[{"given":"Maryam","family":"Lotfi Shahreza","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6519-6548","authenticated-orcid":false,"given":"Nasser","family":"Ghadiri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6039-2355","authenticated-orcid":false,"given":"James R.","family":"Green","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2020,6,1]]},"reference":[{"key":"65658_CR1","doi-asserted-by":"publisher","first-page":"346","DOI":"10.1093\/bib\/bbr021","volume":"12","author":"D Sardana","year":"2011","unstructured":"Sardana, D. et al. Drug repositioning for orphan diseases. Briefings in bioinformatics 12, 346\u2013356, https:\/\/doi.org\/10.1093\/bib\/bbr021 (2011).","journal-title":"Briefings in bioinformatics"},{"key":"65658_CR2","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1517\/21678707.2016.1120664","volume":"4","author":"BE Bloom","year":"2016","unstructured":"Bloom, B. E. Recent successes and future predictions on drug repurposing for rare diseases. Expert Opinion on Orphan Drugs 4, 1\u20134, https:\/\/doi.org\/10.1517\/21678707.2016.1120664 (2016).","journal-title":"Expert Opinion on Orphan Drugs"},{"key":"65658_CR3","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1016\/j.ddstr.2011.10.003","volume":"8","author":"R Muthyala","year":"2011","unstructured":"Muthyala, R. Orphan\/rare drug discovery through drug repositioning. Drug Discovery Today: Therapeutic Strategies 8, 71\u201376, https:\/\/doi.org\/10.1016\/j.ddstr.2011.10.003 (2011).","journal-title":"Drug Discovery Today: Therapeutic Strategies"},{"key":"65658_CR4","doi-asserted-by":"publisher","first-page":"66","DOI":"10.3390\/cancers8070066","volume":"8","author":"K Ahmed","year":"2016","unstructured":"Ahmed, K., Shaw, H. V., Koval, A. & Katanaev, V. L. A Second WNT for Old Drugs: Drug Repositioning against WNT-Dependent Cancers. Cancers 8, 66, https:\/\/doi.org\/10.3390\/cancers8070066 (2016).","journal-title":"Cancers"},{"key":"65658_CR5","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1016\/j.jbi.2017.03.006","volume":"68","author":"M Lotfi Shahreza","year":"2017","unstructured":"Lotfi Shahreza, M., Ghadiri, N., Mousavi, S. R., Varshosaz, J. & Green, J. R. Heter-LP: A heterogeneous label propagation algorithm and its application in drug repositioning. Journal of Biomedical Informatics 68, 167\u2013183, https:\/\/doi.org\/10.1016\/j.jbi.2017.03.006 (2017).","journal-title":"Journal of Biomedical Informatics"},{"key":"65658_CR6","doi-asserted-by":"publisher","first-page":"3458","DOI":"10.1158\/1078-0432.CCR-15-2256","volume":"22","author":"K Satoh","year":"2016","unstructured":"Satoh, K. et al. Identification of Niclosamide as a Novel Anticancer Agent for Adrenocortical Carcinoma. Clinical cancer research: an official journal of the American Association for Cancer Research 22, 3458\u20133466, https:\/\/doi.org\/10.1158\/1078-0432.CCR-15-2256 (2016).","journal-title":"Clinical cancer research: an official journal of the American Association for Cancer Research"},{"issue":"Suppl 7","key":"65658_CR7","doi-asserted-by":"publisher","first-page":"vii131","DOI":"10.1093\/annonc\/mds231","volume":"23","author":"A Berruti","year":"2012","unstructured":"Berruti, A. et al. Adrenal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Annals of oncology: official journal of the European Society for Medical Oncology 23(Suppl 7), vii131\u2013138, https:\/\/doi.org\/10.1093\/annonc\/mds231 (2012).","journal-title":"Annals of oncology: official journal of the European Society for Medical Oncology"},{"key":"65658_CR8","doi-asserted-by":"publisher","first-page":"45","DOI":"10.3389\/fcell.2015.00045","volume":"3","author":"R Lib\u00e9","year":"2015","unstructured":"Lib\u00e9, R. Adrenocortical carcinoma (ACC): diagnosis, prognosis, and treatment. Frontiers in Cell and Developmental Biology 3, 45, https:\/\/doi.org\/10.3389\/fcell.2015.00045 (2015).","journal-title":"Frontiers in Cell and Developmental Biology"},{"key":"65658_CR9","doi-asserted-by":"publisher","first-page":"R405","DOI":"10.1530\/erc-18-0138","volume":"25","author":"J Crona","year":"2018","unstructured":"Crona, J., Beuschlein, F., Pacak, K. & Skogseid, B. Advances in adrenal tumors 2018. Endocrine-related cancer 25, R405\u2013r420, https:\/\/doi.org\/10.1530\/erc-18-0138 (2018).","journal-title":"Endocrine-related cancer"},{"key":"65658_CR10","doi-asserted-by":"publisher","first-page":"657","DOI":"10.1677\/erc.1.01025","volume":"12","author":"A Berruti","year":"2005","unstructured":"Berruti, A. et al. Etoposide, doxorubicin and cisplatin plus mitotane in the treatment of advanced adrenocortical carcinoma: a large prospective phase II trial. Endocrine-related cancer 12, 657\u2013666, https:\/\/doi.org\/10.1677\/erc.1.01025 (2005).","journal-title":"Endocrine-related cancer"},{"key":"65658_CR11","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1155\/2012\/234726","volume":"2012","author":"AH Lebastchi","year":"2012","unstructured":"Lebastchi, A. H., Kunstman, J. W. & Carling, T. Adrenocortical Carcinoma: Current Therapeutic State-of-the-Art. Journal of Oncology 2012, 11, https:\/\/doi.org\/10.1155\/2012\/234726 (2012).","journal-title":"Journal of Oncology"},{"key":"65658_CR12","unstructured":"Cabezon-Gutierrez, L. et al. Clinical Case of Metastatic Adrenocortical Carcinoma With Unusual Evolution: Review the Literature. (2016)."},{"key":"65658_CR13","first-page":"222","volume":"1","author":"DF Maluf","year":"2011","unstructured":"Maluf, D. F., de Oliveira, B. H. & Lalli, E. Therapy of adrenocortical cancer: present and future. American Journal of Cancer Research 1, 222\u2013232 (2011).","journal-title":"American Journal of Cancer Research"},{"issue":"16","key":"65658_CR14","doi-asserted-by":"publisher","first-page":"2004","DOI":"10.1093\/bioinformatics\/btt307","volume":"29","author":"Salvatore Alaimo","year":"2013","unstructured":"Alaimo, S., Pulvirenti, A., Giugno, R. & Ferro, A. Drug-target interaction prediction through domain-tuned network-based inference. Bioinformatics (Oxford, England) 29, https:\/\/doi.org\/10.1093\/bioinformatics\/btt307 (2013).","journal-title":"Bioinformatics"},{"key":"65658_CR15","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/1752-0509-9-s3-s4","volume":"9","author":"S Alaimo","year":"2015","unstructured":"Alaimo, S. et al. DT-Web: a web-based application for drug-target interaction and drug combination prediction through domain-tuned network-based inference. BMC Systems Biology 9, 1\u201311, https:\/\/doi.org\/10.1186\/1752-0509-9-s3-s4 (2015).","journal-title":"BMC Systems Biology"},{"key":"65658_CR16","doi-asserted-by":"publisher","first-page":"443","DOI":"10.3332\/ecancer.2014.443","volume":"8","author":"P Pantziarka","year":"2014","unstructured":"Pantziarka, P., Bouche, G., Meheus, L., Sukhatme, V. & Sukhatme, V. P. Repurposing Drugs in Oncology (ReDO)\u2014mebendazole as an anti-cancer agent. ecancermedicalscience 8, 443, https:\/\/doi.org\/10.3332\/ecancer.2014.443 (2014).","journal-title":"ecancermedicalscience"},{"key":"65658_CR17","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1186\/1479-5876-10-198","volume":"10","author":"N Nilubol","year":"2012","unstructured":"Nilubol, N. et al. Four clinically utilized drugs were identified and validated for treatment of adrenocortical cancer using quantitative high-throughput screening. Journal of Translational Medicine 10, 198\u2013198, https:\/\/doi.org\/10.1186\/1479-5876-10-198 (2012).","journal-title":"Journal of Translational Medicine"},{"key":"65658_CR18","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1093\/jjco\/hyn146","volume":"39","author":"J-O Lee","year":"2009","unstructured":"Lee, J.-O. et al. Metastatic Adrenocortical Carcinoma Treated with Sunitinib: A Case Report. Japanese Journal of Clinical Oncology 39, 183\u2013185, https:\/\/doi.org\/10.1093\/jjco\/hyn146 (2009).","journal-title":"Japanese Journal of Clinical Oncology"},{"key":"65658_CR19","doi-asserted-by":"publisher","first-page":"2189","DOI":"10.1056\/NEJMoa1200966","volume":"366","author":"M Fassnacht","year":"2012","unstructured":"Fassnacht, M. et al. Combination Chemotherapy in Advanced Adrenocortical Carcinoma. New England Journal of Medicine 366, 2189\u20132197, https:\/\/doi.org\/10.1056\/NEJMoa1200966 (2012).","journal-title":"New England Journal of Medicine"},{"key":"65658_CR20","doi-asserted-by":"publisher","first-page":"R1","DOI":"10.1530\/eje-14-0273","volume":"171","author":"CL Ronchi","year":"2014","unstructured":"Ronchi, C. L., Kroiss, M., Sbiera, S., Deutschbein, T. & Fassnacht, M. EJE PRIZE 2014: Current and evolving treatment options in adrenocortical carcinoma: where do we stand and where do we want to go? European journal of endocrinology 171, R1\u2013R11, https:\/\/doi.org\/10.1530\/eje-14-0273 (2014).","journal-title":"European journal of endocrinology"},{"key":"65658_CR21","doi-asserted-by":"publisher","DOI":"10.1186\/s13023-014-0164-y","volume":"9","author":"P Nony","year":"2014","unstructured":"Nony, P. et al. A methodological framework for drug development in rare diseases. Orphanet Journal of Rare Diseases 9, 164, https:\/\/doi.org\/10.1186\/s13023-014-0164-y (2014).","journal-title":"Orphanet Journal of Rare Diseases"},{"key":"65658_CR22","doi-asserted-by":"publisher","first-page":"878","DOI":"10.1093\/bib\/bbx017","volume":"19","author":"M Lotfi Shahreza","year":"2018","unstructured":"Lotfi Shahreza, M., Ghadiri, N., Mousavi, S. R., Varshosaz, J. & Green, J. R. A review of network-based approaches to drug repositioning. Briefings in bioinformatics 19, 878\u2013892, https:\/\/doi.org\/10.1093\/bib\/bbx017 (2018).","journal-title":"Briefings in bioinformatics"},{"issue":"13","key":"65658_CR23","doi-asserted-by":"publisher","first-page":"i232","DOI":"10.1093\/bioinformatics\/btn162","volume":"24","author":"Y. Yamanishi","year":"2008","unstructured":"Yamanishi, Y., Araki, M., Gutteridge, A., Honda, W. & Kanehisa, M. Prediction of drug-target interaction networks from the integration of chemical and genomic spaces. Bioinformatics (Oxford, England) 24, https:\/\/doi.org\/10.1093\/bioinformatics\/btn162 (2008).","journal-title":"Bioinformatics"},{"issue":"2","key":"65658_CR24","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1093\/bioinformatics\/bts670","volume":"29","author":"Jian-Ping Mei","year":"2012","unstructured":"Mei, J.-P., Kwoh, C.-K., Yang, P., Li, X.-L. & Zheng, J. Drug-Target Interaction Prediction by Learning From Local Information and Neighbors. Bioinformatics (Oxford, England), https:\/\/doi.org\/10.1093\/bioinformatics\/bts670 (2012).","journal-title":"Bioinformatics"},{"key":"65658_CR25","doi-asserted-by":"publisher","first-page":"3036","DOI":"10.1093\/bioinformatics\/btr500","volume":"27","author":"T van Laarhoven","year":"2011","unstructured":"van Laarhoven, T., Nabuurs, S. B. & Marchiori, E. Gaussian interaction profile kernels for predicting drug-target interaction. Bioinformatics 27, 3036\u20133043, https:\/\/doi.org\/10.1093\/bioinformatics\/btr500 (2011).","journal-title":"Bioinformatics"},{"issue":"18","key":"65658_CR26","doi-asserted-by":"publisher","first-page":"2397","DOI":"10.1093\/bioinformatics\/btp433","volume":"25","author":"Kevin Bleakley","year":"2009","unstructured":"Bleakley, K. & Yamanishi, Y. Supervised prediction of drug-target interactions using bipartite local models. Bioinformatics (Oxford, England) 25, https:\/\/doi.org\/10.1093\/bioinformatics\/btp433 (2009).","journal-title":"Bioinformatics"},{"key":"65658_CR27","doi-asserted-by":"publisher","first-page":"520","DOI":"10.1039\/C5MB00615E","volume":"12","author":"X-Y Yan","year":"2016","unstructured":"Yan, X.-Y., Zhang, S.-W. & Zhang, S.-Y. Prediction of drug-target interaction by label propagation with mutual interaction information derived from heterogeneous network. Molecular BioSystems 12, 520\u2013531, https:\/\/doi.org\/10.1039\/C5MB00615E (2016).","journal-title":"Molecular BioSystems"},{"key":"65658_CR28","doi-asserted-by":"publisher","first-page":"e1002503","DOI":"10.1371\/journal.pcbi.1002503","volume":"8","author":"F Cheng","year":"2012","unstructured":"Cheng, F. et al. Prediction of drug-target interactions and drug repositioning via network-based inference. PLoS computational biology 8, e1002503, https:\/\/doi.org\/10.1371\/journal.pcbi.1002503 (2012).","journal-title":"PLoS computational biology"},{"key":"65658_CR29","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/1752-0509-4-s2-s6","volume":"4","author":"Z Xia","year":"2010","unstructured":"Xia, Z., Wu, L.-Y., Zhou, X. & Wong, S. T. Semi-supervised drug-protein interaction prediction from heterogeneous biological spaces. BMC Systems Biology 4, 1\u201316, https:\/\/doi.org\/10.1186\/1752-0509-4-s2-s6 (2010).","journal-title":"BMC Systems Biology"},{"key":"65658_CR30","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1089\/cmb.2010.0213","volume":"18","author":"L Perlman","year":"2011","unstructured":"Perlman, L., Gottlieb, A., Atias, N., Ruppin, E. & Sharan, R. Combining Drug and Gene Similarity Measures for Drug-Target Elucidation. Journal of Computational Biology 18, 133\u2013145, https:\/\/doi.org\/10.1089\/cmb.2010.0213 (2011).","journal-title":"Journal of Computational Biology"},{"key":"65658_CR31","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1530\/erc-12-0403","volume":"20","author":"M Jain","year":"2013","unstructured":"Jain, M. et al. TOP2A is overexpressed and is a therapeutic target for adrenocortical carcinoma. Endocrine-related cancer 20, 361\u2013370, https:\/\/doi.org\/10.1530\/erc-12-0403 (2013).","journal-title":"Endocrine-related cancer"},{"key":"65658_CR32","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1530\/eje.1.02011","volume":"153","author":"L Barzon","year":"2005","unstructured":"Barzon, L. et al. Shift from Conn\u2019s syndrome to Cushing\u2019s syndrome in a recurrent adrenocortical carcinoma. European journal of endocrinology 153, 629\u2013636, https:\/\/doi.org\/10.1530\/eje.1.02011 (2005).","journal-title":"European journal of endocrinology"},{"key":"65658_CR33","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1136\/jclinpath-2017-204503","volume":"71","author":"M Pennanen","year":"2018","unstructured":"Pennanen, M. et al. C-myc expression in adrenocortical tumours. Journal of clinical pathology 71, 129\u2013134, https:\/\/doi.org\/10.1136\/jclinpath-2017-204503 (2018).","journal-title":"Journal of clinical pathology"},{"key":"65658_CR34","doi-asserted-by":"publisher","first-page":"941","DOI":"10.1200\/jco.2002.20.4.941","volume":"20","author":"A Stojadinovic","year":"2002","unstructured":"Stojadinovic, A. et al. Adrenocortical carcinoma: clinical, morphologic, and molecular characterization. Journal of clinical oncology: official journal of the American Society of Clinical Oncology 20, 941\u2013950, https:\/\/doi.org\/10.1200\/jco.2002.20.4.941 (2002).","journal-title":"Journal of clinical oncology: official journal of the American Society of Clinical Oncology"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-020-65658-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-020-65658-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-020-65658-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,6]],"date-time":"2022-12-06T12:02:14Z","timestamp":1670328134000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-020-65658-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,6,1]]},"references-count":34,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2020,12]]}},"alternative-id":["65658"],"URL":"https:\/\/doi.org\/10.1038\/s41598-020-65658-x","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,6,1]]},"assertion":[{"value":"11 December 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 May 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 June 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"8846"}}